In conclusion, compared with the same dose of TPL-NS, the TPL-NS-Gel group had significantly improved joint swelling and stiffness in the rat RA model and significantly reduced levels of IL-1, IL-6, TNF-α and hs-CRP. This evidence concerns the gene IL1A and rheumatoid arthritis.